The indications of polyethylene glycol recombinant human growth hormone injection such as idiopathic short stature (ISS) and growth disorders in children caused by congenital ovarian hypoplasia syndrome (Turner syndrome) have entered the marketing review stage; the addition of the indication of small for gestational age (SGA) has completed the Phase II clinical trial; the indication of adult growth hormone deficiency has launched the Phase III clinical trial, and patient enrollment is in progress.